Special Considerations in People With HIV
Last Updated: March 6, 2023
Prevention of COVID-19
Diagnosis of COVID-19
Management of COVID-19
Management of HIV
|Each recommendation in the Guidelines receives a rating for the strength of the recommendation (A, B, or C) and a rating for the evidence that supports it (I, IIa, IIb, or III). See Guidelines Development for more information.|
Approximately 1.2 million people in the United States are living with HIV. Most of these individuals are in care, and many are receiving antiretroviral therapy (ART) and have well-controlled disease.1 Similar to COVID-19, HIV disproportionately affects racial and ethnic minorities and people living in low-income settings in the United States; these demographic groups also appear to have a higher risk of poor outcomes with COVID-19.2 Many people with HIV have 1 or more comorbidities or conditions that may put them at increased risk for a more severe course of COVID-19.3
Information on SARS-CoV-2/HIV coinfection is evolving rapidly. The sections below outline the current knowledge regarding preventing and diagnosing SARS-CoV-2 infection in people with HIV, treatment and clinical outcomes in people with HIV who develop COVID-19, and management of HIV during the COVID-19 pandemic. In addition to these Guidelines, the Guidelines Working Groups of the National Institutes of Health Office of AIDS Research Advisory Council has developed Guidance for COVID-19 and People With HIV.
Clinical Outcomes of COVID-19 in People With HIV
Data are emerging on the clinical outcomes of COVID-19 in people with HIV. In some of the initial case series of people with COVID-19 in Europe and the United States, no significant differences were observed in the clinical outcomes of COVID-19 between people with HIV and people who did not have HIV.4-11
In contrast, more recent reports suggest worse outcomes for patients with HIV and COVID-19, including increased COVID-19 mortality in cohort studies in the United States, the United Kingdom, and South Africa.12-18 HIV was independently associated with an increased risk of severe and critical COVID-19 in a large World Health Organization platform trial that included data from 24 countries.19 In a multicenter cohort study of 286 patients with HIV and COVID-19 in the United States, lower CD4 T lymphocyte (CD4) cell counts (i.e., <200 cells/mm3) were associated with a higher risk for the composite endpoint of intensive care unit admission, mechanical ventilation, or death.15 This increased risk was observed even in patients who had achieved virologic suppression of HIV. In a large observational cohort study of people with HIV and COVID-19 in the United States, those with CD4 counts <350 cells/mm3 were more likely to be hospitalized, require ventilation, or die.18 Higher levels of viremia were also associated with worse outcomes. In another study of 175 patients with HIV and COVID-19, a low CD4 count or a low CD4 nadir was associated with poor outcomes.16 In a cohort study conducted in New York, people with HIV and COVID-19 had higher rates of hospitalization and mortality than people with COVID-19 who did not have HIV.17
Prevention of COVID-19 in People With HIV
The COVID-19 Treatment Guidelines Panel (the Panel) recommends using the same approach for advising people with HIV on the strategies to prevent SARS-CoV-2 infection that is used for people without HIV (AIII). There is currently no clear evidence that any antiretroviral (ARV) medications can prevent SARS-CoV-2 infection.
The Panel recommends that people with HIV receive COVID-19 vaccines, regardless of their CD4 cell count or HIV viral load, because the potential benefits outweigh the potential risks (AIII). People with HIV were included in the clinical trials of the 2 mRNA vaccines and the adenovirus vector vaccine that are currently available through Emergency Use Authorizations (EUAs) and/or approval from the Food and Drug Administration (FDA);20-22 however, few studies have evaluated the safety and efficacy of these vaccines in people with HIV. Typically, people with HIV who are receiving ART and who have achieved virologic suppression respond well to licensed vaccines. Preliminary data from studies that used COVID-19 vaccines in people with HIV confirm that people who are receiving ART and have normal CD4 counts have good immunologic responses to the vaccines.23-25
On August 12, 2021, the FDA changed the EUAs for the 2 mRNA vaccines to allow a third dose of an mRNA vaccine to be administered at least 28 days after the second dose to people with advanced or untreated HIV. Advanced HIV is defined as people with CD4 counts <200 cells/mm3, a history of an AIDS-defining illness without immune reconstitution, or clinical manifestations of symptomatic HIV. People with HIV should also receive booster doses of COVID-19 vaccines as recommended by the Advisory Committee on Immunization Practices.26
Diagnostic and Laboratory Testing for COVID-19 in People With HIV
Diagnosis of COVID-19 in People With HIV
The Panel recommends using the same approach for diagnosing SARS-CoV-2 infection in people with HIV as in people without HIV (AIII). See Testing for SARS-CoV-2 Infection for more information. There is currently no evidence that the performance characteristics of nucleic acid amplification tests (NAATs) and antigen tests differ in people with and without HIV when diagnosing acute SARS-CoV-2 infection. The Panel recommends against the use of serologic testing as the sole basis for diagnosis of acute SARS-CoV-2 infection (AIII). However, if diagnostic serologic testing is performed in a patient with HIV, the results should be interpreted with caution because cross-reactivity between antibodies to SARS-CoV-2 and HIV has been reported.27
Correlation of CD4 Count in People With HIV and COVID-19
The normal range for CD4 counts in healthy adults is about 500 to 1,600 cells/mm3. People with HIV who have a CD4 count of ≥500 cells/mm3 have similar cellular immune function to those without HIV. In people with HIV, a CD4 count <200 cells/mm3 meets the definition for AIDS. For patients receiving ART, the hallmark of treatment success is plasma HIV RNA below the level of detection by a polymerase chain reaction assay. Lymphopenia is a common laboratory finding in patients with COVID-19; in patients with HIV, clinicians should note that CD4 counts obtained during acute COVID-19 may not accurately reflect the patient’s HIV disease stage.
There have been some reports of people with advanced HIV who have presented with COVID-19 and another coinfection, including Pneumocystis jirovecii pneumonia.28,29 In patients with advanced HIV who have suspected or laboratory-confirmed SARS-CoV-2 infection, clinicians should consider HIV-associated opportunistic infections in the differential diagnosis of clinical symptoms and consider consulting an HIV specialist (AIII).
Clinical Presentation of COVID-19 in People With HIV
It is currently unknown whether people with HIV have a higher incidence of SARS-CoV-2 infection or a higher rate of progression to symptomatic disease than the general population. Approximately 50% of people with HIV in the United States are aged >50 years,30 and many have comorbidities that are associated with more severe cases of COVID-19. These comorbidities include hypertension, diabetes mellitus, cardiovascular disease, a history of smoking, chronic lung disease, chronic liver disease, and cancer.31
There are a number of case reports and case series that describe the clinical presentation of COVID-19 in people with HIV.4-11,32,33 These studies indicate that the clinical presentation of COVID-19 is similar in people with and without HIV. Most of the published reports describe populations in which most of the individuals with HIV are receiving ART and have achieved virologic suppression. Consequently, the current understanding of the impact of COVID-19 in people with advanced HIV and low CD4 counts or persistent HIV viremia is limited.
Management of COVID-19 in People With HIV
Recommendations for the triage and management of COVID-19 in people with HIV are the same as those for the general population (AIII).
The treatment of COVID-19 in persons with HIV is the same as for those without HIV (AIII). Nonhospitalized people with HIV and mild to moderate COVID-19 may be eligible to receive the therapies that are currently recommended for treatment (see Therapeutic Management of Nonhospitalized Adults With COVID-19). However, in situations where there are logistical or supply constraints for administering these therapies, priority should be given to those with advanced HIV (AIII).
When starting treatment for COVID-19 in patients with HIV, clinicians should pay careful attention to potential drug-drug interactions and overlapping toxicities among COVID-19 treatments, ARV medications, antimicrobial therapies, and other medications (AIII). Therapeutic options for nonhospitalized patients with HIV include ritonavir-boosted nirmatrelvir (Paxlovid), intravenous remdesivir, and molnupiravir.
Drug-drug interactions are a special concern with ritonavir-boosted nirmatrelvir (see Drug-Drug Interactions Between Ritonavir-Boosted Nirmatrelvir [Paxlovid] and Concomitant Medications). People with HIV who are receiving ritonavir-based or cobicistat-based ART can receive the 5-day course of ritonavir-boosted nirmatrelvir to treat COVID-19 without altering or interrupting their ART (i.e., they can continue using the ritonavir or cobicistat dose associated with their ART in addition to the dose of ritonavir used with nirmatrelvir). Before prescribing ritonavir-boosted nirmatrelvir for a patient who is not already on a ritonavir-based or cobicistat-based regimen, clinicians should carefully review the patient’s concomitant medications, including over-the-counter medicines and herbal supplements, and evaluate the potential for drug-drug interactions. Clinicians should utilize resources such as the FDA’s EUA fact sheet for ritonavir-boosted nirmatrelvir and the Liverpool COVID-19 Drug Interactions website for additional guidance on identifying and managing drug-drug interactions.
In hospitalized patients, the appropriate treatment strategy depends on disease severity (see Therapeutic Management of Hospitalized Adults With COVID-19). Both tocilizumab and dexamethasone, which are recommended for some patients with severe or critical COVID-19, are immunosuppressive agents. The safety of using these drugs in patients who are immunocompromised, including those with advanced HIV, has not been studied. Therefore, patients with advanced HIV who are receiving these drugs should be closely monitored for secondary infections.
Dexamethasone is a dose-dependent inducer of cytochrome P450 3A4 and could potentially lower the levels of certain coadministered ARV drugs. More than a single dose of dexamethasone is not recommended for patients receiving rilpivirine as part of their ARV regimen. Clinicians should consult an HIV specialist before administering dexamethasone to these patients. It is currently unknown whether administering ≤10 days of dexamethasone impacts the clinical efficacy of other ARV drugs. Patients with HIV who are receiving dexamethasone as treatment for COVID-19 should follow up with their HIV providers to assess their virologic response.
Although some ARV drugs were studied for the prevention and treatment of COVID-19, no agents have been shown to be effective.
People with HIV should be offered the opportunity to participate in clinical trials of vaccines and potential treatments for COVID-19. A variety of immunomodulatory therapies are prescribed empirically or administered as part of a clinical trial to treat severe COVID-19. The data on whether these medications are safe to use in patients with HIV are lacking. If a medication has been shown to reduce the mortality of patients with COVID-19 in the general population, it should also be used to treat COVID-19 in patients with HIV, unless data indicate that the medication is not safe or effective in this population.
Managing HIV in People With COVID-19
People with HIV who develop COVID-19, including those who require hospitalization, should continue their ART and opportunistic infection treatment and prophylaxis whenever possible (AIII). Treatment interruption may lead to rebound viremia, and, in some cases, the emergence of drug resistance. If the appropriate ARV drugs are not on the hospital’s formulary, administer medications from the patient’s home supplies, if available.
Clinicians treating COVID-19 in people with HIV should consult an HIV specialist before adjusting or switching a patient’s ARV medications (AIII). An ARV regimen should not be switched or adjusted (i.e., by adding ARV drugs to the regimen) for the purpose of preventing or treating SARS-CoV-2 infection (AIII). Many drugs, including some ARV agents (e.g., lopinavir/ritonavir, boosted darunavir, tenofovir disoproxil fumarate/emtricitabine), have been or are being evaluated in clinical trials or are prescribed off-label to treat or prevent SARS-CoV-2 infection. To date, lopinavir/ritonavir and darunavir/cobicistat have not been found to be effective.34,35 Two retrospective studies have suggested that tenofovir disoproxil fumarate/emtricitabine may play a role in preventing SARS-CoV-2 acquisition or hospitalization or death associated with COVID-19; however, the significance of these findings is unclear, as neither study adequately controlled for confounding variables such as age and comorbidities.12,33
For patients receiving an investigational ARV medication as part of their ARV regimen, arrangements should be made with the investigational study team to continue the medication, if possible.
For critically ill patients who require tube feeding, some ARV medications are available in liquid formulations, and some ARV pills may be crushed. Clinicians should consult an HIV specialist and/or pharmacist to assess the best way to continue an effective ARV regimen for a patient with a feeding tube. Information may be available in the drug product label or from the Toronto General Hospital.
For people who present with COVID-19 and have either a new diagnosis of HIV or a history of HIV but are not receiving ART, the optimal time to start or restart ART is currently unknown. For people with HIV who have not initiated ART or who have been off therapy for >2 weeks before presenting with COVID-19, an HIV specialist should be consulted about initiating or reinitiating ART as soon as clinically feasible. If ART is initiated, maintaining treatment and linking patients to HIV care upon hospital discharge is critical. If an HIV specialist is not available, clinical consultation is available by phone through the National Clinician Consultation Center, Monday through Friday, 9 am to 8 pm EST.
- Harris NS, Johnson AS, Huang YA, et al. Vital signs: status of human immunodeficiency virus testing, viral suppression, and HIV preexposure prophylaxis—United States, 2013-2018. MMWR Morb Mortal Wkly Rep. 2019;68(48):1117-1123. Available at: https://www.ncbi.nlm.nih.gov/pubmed/31805031.
- Meyerowitz EA, Kim AY, Ard KL, et al. Disproportionate burden of coronavirus disease 2019 among racial minorities and those in congregate settings among a large cohort of people with HIV. AIDS. 2020;34(12):1781-1787. Available at: https://www.ncbi.nlm.nih.gov/pubmed/32604138.
- Centers for Disease Control and Prevention. Underlying medical conditions associated with higher risk for severe COVID-19: information for healthcare professionals. 2023. Available at: https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/underlyingconditions.html. Accessed February 15, 2023.
- Gervasoni C, Meraviglia P, Riva A, et al. Clinical features and outcomes of patients with human immunodeficiency virus with COVID-19. Clin Infect Dis. 2020;71(16):2276-2278. Available at: https://www.ncbi.nlm.nih.gov/pubmed/32407467.
- Härter G, Spinner CD, Roider J, et al. COVID-19 in people living with human immunodeficiency virus: a case series of 33 patients. Infection. 2020;48(5):681-686. Available at: https://www.ncbi.nlm.nih.gov/pubmed/32394344.
- Karmen-Tuohy S, Carlucci PM, Zervou FN, et al. Outcomes among HIV-positive patients hospitalized with COVID-19. J Acquir Immune Defic Syndr. 2020;85(1):6-10. Available at: https://www.ncbi.nlm.nih.gov/pubmed/32568770.
- Patel VV, Felsen UR, Fisher M, et al. Clinical outcomes and inflammatory markers by HIV serostatus and viral suppression in a large cohort of patients hospitalized with COVID-19. J Acquir Immune Defic Syndr. 2021;86(2):224-230. Available at: https://www.ncbi.nlm.nih.gov/pubmed/33433966.
- Shalev N, Scherer M, LaSota ED, et al. Clinical characteristics and outcomes in people living with human immunodeficiency virus hospitalized for coronavirus disease 2019. Clin Infect Dis. 2020;71(16):2294-2297. Available at: https://www.ncbi.nlm.nih.gov/pubmed/32472138.
- Sigel K, Swartz T, Golden E, et al. Coronavirus 2019 and people living with human immunodeficiency virus: outcomes for hospitalized patients in New York City. Clin Infect Dis. 2020;71(11):2933-2938. Available at: https://www.ncbi.nlm.nih.gov/pubmed/32594164.
- Stoeckle K, Johnston CD, Jannat-Khah DP, et al. COVID-19 in hospitalized adults with HIV. Open Forum Infect Dis. 2020;7(8):ofaa327. Available at: https://www.ncbi.nlm.nih.gov/pubmed/32864388.
- Vizcarra P, Pérez-Elías MJ, Quereda C, et al. Description of COVID-19 in HIV-infected individuals: a single-centre, prospective cohort. Lancet HIV. 2020;7(8):e554-e564. Available at: https://www.ncbi.nlm.nih.gov/pubmed/32473657.
- Western Cape Department of Health in collaboration with the National Institute for Communicable Diseases South Africa. Risk factors for coronavirus disease 2019 (COVID-19) death in a population cohort study from the Western Cape Province, South Africa. Clin Infect Dis. 2021;73(7):e2005-e2015. Available at: https://www.ncbi.nlm.nih.gov/pubmed/32860699.
- Bhaskaran K, Rentsch CT, MacKenna B, et al. HIV infection and COVID-19 death: a population-based cohort analysis of UK primary care data and linked national death registrations within the OpenSAFELY platform. Lancet HIV. 2021;8(1):e24-e32. Available at: https://www.ncbi.nlm.nih.gov/pubmed/33316211.
- Geretti AM, Stockdale AJ, Kelly SH, et al. Outcomes of coronavirus disease 2019 (COVID-19) related hospitalization among people with human immunodeficiency virus (HIV) in the ISARIC World Health Organization (WHO) clinical characterization protocol (UK): a prospective observational study. Clin Infect Dis. 2021;73(7):e2095-e2106. Available at: https://www.ncbi.nlm.nih.gov/pubmed/33095853.
- Dandachi D, Geiger G, Montgomery MW, et al. Characteristics, comorbidities, and outcomes in a multicenter registry of patients with human immunodeficiency virus and coronavirus disease 2019. Clin Infect Dis. 2021;73(7):e1964-e1972. Available at: https://www.ncbi.nlm.nih.gov/pubmed/32905581.
- Hoffmann C, Casado JL, Härter G, et al. Immune deficiency is a risk factor for severe COVID-19 in people living with HIV. HIV Med. 2021;22(5):372-378. Available at: https://www.ncbi.nlm.nih.gov/pubmed/33368966.
- Tesoriero JM, Swain CE, Pierce JL, et al. COVID-19 outcomes among persons living with or without diagnosed HIV infection in New York State. JAMA Netw Open. 2021;4(2):e2037069. Available at: https://www.ncbi.nlm.nih.gov/pubmed/33533933.
- Sun J, Patel RC, Zheng Q, et al. COVID-19 disease severity among people with HIV infection or solid organ transplant in the United States: a nationally-representative, multicenter, observational cohort study. medRxiv. 2021;Preprint. Available at: https://www.ncbi.nlm.nih.gov/pubmed/34341798.
- World Health Organization. Clinical characteristics and prognostic factors in people living with HIV hospitalized with COVID-19: findings from the WHO global clinical platform. 2021. Available at: https://www.who.int/publications/i/item/WHO-2019-nCoV-Clinical-HIV-2021.1.
- Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403-416. Available at: https://www.ncbi.nlm.nih.gov/pubmed/33378609.
- Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med. 2020;383(27):2603-2615. Available at: https://www.ncbi.nlm.nih.gov/pubmed/33301246.
- Food and Drug Administration. Fact sheet for healthcare providers administering vaccine (vaccination providers): Emergency Use Authorization (EUA) of the Janssen COVID-19 vaccine to prevent coronavirus disease 2019 (COVID-19). 2022. Available at: https://www.fda.gov/media/146304/download.
- Levy I, Wieder-Finesod A, Litchevsky V, et al. Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in people living with HIV-1. Clin Microbiol Infect. 2021;27(12):1851-1855. Available at: https://www.ncbi.nlm.nih.gov/pubmed/34438069.
- Woldemeskel BA, Karaba AH, Garliss CC, et al. The BNT162b2 mRNA vaccine elicits robust humoral and cellular immune responses in people living with human immunodeficiency virus (HIV). Clin Infect Dis. 2022;74(7):1268-1270. Available at: https://www.ncbi.nlm.nih.gov/pubmed/34293114.
- Frater J, Ewer KJ, Ogbe A, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial. Lancet HIV. 2021;8(8):e474-e485. Available at: https://www.ncbi.nlm.nih.gov/pubmed/34153264.
- Centers for Disease Control and Prevention. Use of COVID-19 vaccines in the United States. 2023. Available at: https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html. Accessed February 21, 2023.
- Tan SS, Chew KL, Saw S, Jureen R, Sethi S. Cross-reactivity of SARS-CoV-2 with HIV chemiluminescent assay leading to false-positive results. J Clin Pathol. 2021;74(9):614. Available at: https://www.ncbi.nlm.nih.gov/pubmed/32907911.
- Blanco JL, Ambrosioni J, Garcia F, et al. COVID-19 in patients with HIV: clinical case series. Lancet HIV. 2020;7(5):e314-e316. Available at: https://www.ncbi.nlm.nih.gov/pubmed/32304642.
- Coleman H, Snell LB, Simons R, Douthwaite ST, Lee MJ. Coronavirus disease 2019 and Pneumocystis jirovecii pneumonia: a diagnostic dilemma in HIV. AIDS. 2020;34(8):1258-1260. Available at: https://www.ncbi.nlm.nih.gov/pubmed/32501852.
- Centers for Disease Control and Prevention. Estimated HIV incidence and prevalence in the United States 2014–2018. HIV Surveillance Rep. 2020;25(1):1-78. Available at: https://www.cdc.gov/hiv/pdf/library/reports/surveillance/cdc-hiv-surveillance-supplemental-report-vol-25-1.pdf.
- Kong AM, Pozen A, Anastos K, Kelvin EA, Nash D. Non-HIV comorbid conditions and polypharmacy among people living with HIV age 65 or older compared with HIV-negative individuals age 65 or older in the United States: a retrospective claims-based analysis. AIDS Patient Care STDS. 2019;33(3):93-103. Available at: https://www.ncbi.nlm.nih.gov/pubmed/30844304.
- Byrd KM, Beckwith CG, Garland JM, et al. SARS-CoV-2 and HIV coinfection: clinical experience from Rhode Island, United States. J Int AIDS Soc. 2020;23(7):e25573. Available at: https://www.ncbi.nlm.nih.gov/pubmed/32657527.
- Del Amo J, Polo R, Moreno S, et al. Incidence and severity of COVID-19 in HIV-positive persons receiving antiretroviral therapy: a cohort study. Ann Intern Med. 2020;173(7):536-541. Available at: https://www.ncbi.nlm.nih.gov/pubmed/32589451.
- RECOVERY Collaborative Group. Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2020;396(10259):1345-1352. Available at: https://www.ncbi.nlm.nih.gov/pubmed/33031764.
- Chen J, Xia L, Liu L, et al. Antiviral activity and safety of darunavir/cobicistat for the treatment of COVID-19. Open Forum Infect Dis. 2020;7(7):ofaa241. Available at: https://www.ncbi.nlm.nih.gov/pubmed/32671131.